DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 1 Bruno Bizzozero - 1 Karmel Choi - 1 Choi - 1 – - 1 Brendon Stubbs - 1 Stubbs - 1 Oleg Elkov - 1
Top related locs:
La Mancha Spain Australia Chicago , Illinois U.S Britain England Europe
Top related orgs:
CNN - 1 JAMA - 1 Health and Social Research Centre - 1 University of Castilla - 1 La - 1 Harvard Medical School - 1 National Institute for Health and Care - 1 King’s College London - 1

Search resuls for: "National Institute for Health and Care"


6 mentions found


☆ The next step to treating your depression may be upping your step count, study says
  + stars: | 2024-12-17 | by ( Madeline Holcombe | ) edition.cnn.com   time to read: +5 min
Editor’s note: If you or someone you know is struggling with mental health, help is available. CNN —The steps you take each day could lead you to a reduction in depression symptoms, according to a new study. A study published Monday in the journal JAMA Network Open found that a higher daily step count is associated with fewer depressive symptoms. And taking more steps isn’t the only move you can make toward better mental health, Choi said. “Step count is a nice proxy for physical activity, which has been consistently shown to have beneficial effects on depression risk,” she added.
Persons: ”, Bruno Bizzozero, Karmel Choi, Choi, –, Brendon Stubbs, Stubbs, Oleg Elkov, ” Choi, Michael Noetel, Noetel, ” Noetel Organizations: CNN, JAMA, Health and Social Research Centre, University of Castilla, La, Harvard Medical School, National Institute for Health and Care, King’s College London, of Psychology, University of Queensland Locations: La Mancha, Spain, Australia
☆ Weight-loss drugs pilot to begin in UK amid uncertainty over Wegovy launch
  + stars: | 2023-06-06 | by ( Ludwig Burger Maggie Fick | Ludwig Burger | Maggie Fick | ) www.reuters.com   time to read: +6 min
Novo's inability to keep up with a burst in U.S. demand for Wegovy has effectively delayed the launch in Britain and elsewhere in Europe. A company spokesperson would not comment on any commitment to supply its drug for the British pilot. The British government said that only 35,000 people would have access to Wegovy under the specialist hospital services, but tens of thousands more could be eligible. Duane Mellor, a dietitian and senior lecturer at Aston University's medical school, told Reuters drugs like Wegovy were a tool, not the solution. Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that triggers the feeling of fullness in the body after eating.
Persons: Jim Vondruska, Sunak, Eli Lilly's, Eli Lilly, Phil McEwan, Novo, Keen, Wegovy, Duane Mellor, Simon Cork, Ludwig Burger, Maggie Fick, Anusha, Helen Reid, Lincoln, Mark Potter Organizations: REUTERS, National Health, Novo, British, NHS, NICE, National Institute for Health, Care, Wegovy, Nordisk, ., Heor Ltd, Reuters, Aston, Anglia Ruskin University, Thomson Locations: Chicago , Illinois, U.S, Britain, England, Europe, United States, British, Cardiff, Denmark, Norway, Frankfurt, London, Bengaluru
☆ Do antidepressants prescribed for chronic pain work?
  + stars: | 2023-05-09 | by ( Katie Hunt | ) edition.cnn.com   time to read: +6 min
CNN —Around one-third of people globally live with chronic pain — pain experienced for more than three months — and millions of people are prescribed antidepressants to relieve the condition. However, a new review of prior research published Tuesday has found that most antidepressants used to relieve chronic pain are being prescribed without sufficient reliable evidence of their effectiveness. The studies mainly investigated three types of chronic pain: fibromyalgia, nerve pain and musculoskeletal pain. The most commonly prescribed antidepressant for chronic pain globally was amitriptyline, the study said. Anyone taking antidepressants for chronic pain relief should speak to their doctor before stopping their medication due to concerns over the new report, the authors stressed.
☆ Britain's NICE to speed up reviews of COVID-19 treatments
  + stars: | 2023-02-16 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
LONDON, Feb 16 (Reuters) - Britain's agency that determines if medicines should be used in the National Health Service (NHS) said on Thursday it is speeding up how it decides if COVID-19 therapies are still effective against circulating variants. The new review process will enable the agency to update its recommendations on the cost-effectiveness of COVID treatments so they can be made available more swiftly to patients, it said. "The rapidly evolving nature of COVID-19 means we need to have a way of establishing the cost effectiveness of existing medicines against current variants in an agile way," the National Institute for Health and Care Excellence (NICE) said. It said there is no evidence of Evusheld's clinicial effectiveness against current variants and those likely to be circulating in the next 6 months. The announcement comes as demand for COVID treatments appears set to drop this year, due to population immunity from high rates of vaccination and previous infections.
☆ Fact Check-No evidence COVID-19 mRNA vaccines are significant contributing factor to UK’s 30,000 excess cardiovascular deaths
  + stars: | 2023-01-24 | by ( Reuters Fact Check | ) www.reuters.com   time to read: +5 min
Millions of people have viewed a BBC News interview with a British cardiologist who used the broadcast to spread misinformation about COVID-19 vaccines. Malhotra cites the British Heart Foundation (BHF) for reporting 30,000 excess cardiovascular deaths “during the pandemic or since the pandemic”. A BHF spokesperson told Reuters that there were indeed 30,000 excess deaths involving ischaemic heart disease (IHD) in England between March 2020 and August 2022. Reuters has addressed similar claims linking COVID-19 vaccines with excess mortality (here, here and here), cardiac arrests (here, here and here), and other heart issues. Experts say the 30,000 excess cardiovascular deaths reported since the beginning of the pandemic are due to COVID-19 infection and issues with healthcare services.
☆ Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
  + stars: | 2022-11-16 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.
0 next >>
Total: 6